Slide 1: Cyclopharm Limited Half Year Presentation
For personal use only Cyclopharm Limited Half Year Presentation August 2008
Slide 2: Highlights
Highlights For personal use only ; Strong underlying performance of the Technegas division ; Strong balance sheet ; Strong trading cashflow ; Continued geographic expansion in Europe, Asia and South America ; Technegas submission to the US FDA is 85% complete. Submission planned for second half of 2
Slide 3: Profit & Loss
Profit & Loss For personal use only Profit before tax and finance costs For the half year ended 30 June 2008 30 June 2007 increased 223% to $482,285 (2007: $ $ 149,367). Technegas Division Sales Revenue 4,351,514 4,790,891 Profit before tax and finance costs 594,999 603,982 Whilst Technegas related
Slide 4: Balance Sheet
Balance Sheet For personal use only Balance Sheet Summary 30 June 2008 31 December 2007 $ $ Total Current Assets 8,448,719 7,763,729 Total Non-current Assets 4,160,565 3,213,820 Total Assets 12,609,284 10,977,549 Total Current Liabilities 1,780,009 1,584,918 Total Non-current Liabilities 3,411,219 2
Slide 5: Operating Cashflow
Operating Cashflow For personal use only 30 June 2008 30 June 2007 $ $ Operating activities Receipts from customers 5,532,280 5,748,483 Payments to suppliers and employees (3,879,117) (5,260,962) Other (116,316) (248,944) Net cash flows from operating activities 1,536,847 238,577 Strong trading cash
Slide 6: Molecular Imaging
Molecular Imaging For personal use only Melbourne ‐ Lloyd Street, Kensington 9 Land purchased • Design under development • Construction to commence early 2009 Lloyd Street, Kensington is a proposed asset of Group Sydney – Macquarie University Hospital 9 Design phase completed 9 Bunker construction c
Slide 7: Technegas Divisional Review
Technegas Divisional Review For personal use only Revenue from TechnegasPlus generators and PAS $3.7 m $3.5 m $3.7 m decreased 11% 18 TechnegasPlus generator sales (2007: 48) and 67,000 PAS unit sales (2007: 72,850) were recorded in the first half. Jun '06 Jun '07 Jun '08 Group, PAS Revenue Our gros
Slide 8: Outlook
Outlook For personal use only Continued focus on developing the Molecular Imaging division. We expect to complete construction of the Sydney PET Nuclear Pharmacy this year and fit out to commence in Q1 2009. We expect stronger TechnegasPlus Generator and PAS sales revenue in the second half of 2009